Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
News|Videos|September 10, 2025
Elacestrant Combinations in ER+/HER2- Locally Advanced or Metastatic Breast Cancer: Efficacy and Safety Updates from the Phase 1b/2 ELEVATE Study
Author(s)Hope S. Rugo, MD, FASCO
Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.
Advertisement
Funding supported by Stemline Therapeutics. Content independently developed by OncLive
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5